Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate the treatment of refractory or relapsed DLBCL with
orelabrutinib and gemox. The primary endpoint is response rate (complete response rate and
overall response rate), and the second endpoints are survival time (OS and PFS) and
toxicities.